This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


David Fitzgerald, Ph.D.
Chief Biotherapy Section, Laboratory of Molecular at National Cancer Institute


David FitzGerald, PhD serves as Chief of the Biotherapy Section, Laboratory of Molecular Biology, CCR, NCI.  His undergraduate degree was from Trinity College, Dublin, Ireland and he received his PhD from the U of Cincinnati.  Dr FitzGerald has a life-long interest in antibody-based therapies with particular emphasis on the development of cytotoxic antibodies for treating cancer.  He has played pivotal roles in both the development of recombinant immunotoxins and the use of combination treatments to make immunotoxins more effective.  Because of the need to ‘kill’ cancer cells, Dr FitzGerald and his team also have a keen interest in apoptosis and cell death pathways, attempting to identify biomarkers that predict sensitivity and resistance to various antibody-based therapeutics.

David Fitzgerald, Ph.D.'s Network

Agenda Sessions

  • Development of Cancer-reactive Antibodies Focused to the 287-302 Amino Acid Loop of the Human Epidermal Growth Factor Receptor